Beyond Air, Inc. Stock News

Beyond Air (NASDAQ:XAIR) had its price target raised by equities researchers at Truist Securities from $12.00 to $16.00 in a report issued on Friday, Analyst Price Targets reports. The brokerage presently has a buy rating on the stock. Truist Securities price target suggests a potential upside of 19.40% from the companys current price. A number []

The stock price of Beyond Air Inc (NASDAQ: XAIR) increased 21.82% today. This is why it happened.

Beyond Air, Inc.'s (XAIR) CEO Steve Lisi on Q2 2022 Results - Earnings Call Transcript

Call scheduled for Thursday, November 11th at 4:30 pm Eastern Time Call scheduled for Thursday, November 11th at 4:30 pm Eastern Time

Beyond Air Inc (NASDAQ: XAIR) has announced interim data from Australia's ongoing LungFit GO pilot study.  Related:   Beyond Air Issues Regulatory Update For LungFit PH System.

Beyond Air Inc (NASDAQ: XAIR) announced a regulatory update for the approval process of its LungFit PH system. The Company said that the FDA facility inspections are currently ongoing.

FDA inspection of facilities is ongoing; US commercial launch remains on track for 4Q CY2021, pending FDA approval

GARDEN CITY, N.Y., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for

GARDEN CITY, N.Y., Aug. 20, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for

Beyond Air, Inc. (XAIR) delivered earnings and revenue surprises of -63.16% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Beyond Air, Inc. (XAIR) CEO Steve Lisi on Q1 2022 Results - Earnings Call Transcript

Shares of Beyond Air (NASDAQ:XAIR) rose in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 22.50% year over year to ($0.31), which missed the

U.S. FDA reviewing premarket approval (PMA) submission for LungFit® PH to treat persistent pulmonary hypertension of the newborn (PPHN); On track for commercial launch in the fourth quarter of calend

Beyond Air, Inc. (XAIR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.